Suche
Mein Konto
Groundbreaking cell therapy: new glimmer of hope for brain inflammation!
Researchers at the Charité in Berlin are developing innovative cell therapies to treat the rare NMDA receptor encephalitis.
Groundbreaking cell therapy: new glimmer of hope for brain inflammation!
Autoimmune brain inflammation is a secret wall of neurology, and especially theAnti-NMDA receptor encephalitiscatches many people unprepared. This rare but severe disease causes the immune system to mistakenly attack its own nerve cells, sometimes causing dramatic psychiatric symptoms. Anyone who doesn't get help quickly usually has a bad hand. After about twelve years of unraveling many of the medical mysteries surrounding this disease, we are now on the verge of a real change in treatment.
Researcher of the Charité have developed a novel treatment approach. The body's own immune cells should work with oneChimeric Autoantibody Receptor (CAAR)be equipped. This makes it possible to specifically detect and eliminate disease-causing cells, while the rest of the immune system continues to perform its protective functions.
The path to new therapy
At the heart of this project is the construction of aGMP-compliant gene ferry, which is based on special viruses and makes it possible to introduce the CAAR genetic material into therapeutic cells. A funding amount of around1.5 million eurosensures that implementation progresses. The planned production of theNMDAR-CAAR T cellsat the Berlin Center for Advanced Therapies (BeCAT) is scheduled to start next year or the year after, followed by a first phase I clinical trial on the use of these cells in the treatment of NMDAR encephalitis. Interestingly, this study is being carried out in cooperation with the BecauseY clinical research group.
Anti-NMDA receptor encephalitis not only represents a medical challenge, but its symptoms – such as memory impairment, epileptic seizures and impaired consciousness – have extensive effects on the lives of those affected. These are estimated annually200 to 300 peoplein Germany, with a striking ratio of women to men of around 8:2.
A step into the future
Diagnosing the disease is also no walk in the park. It is often challenging to distinguish symptoms from primary psychiatric disorders. This is where research comes into play: animal models reveal the complex mechanisms of the disease and could help develop new treatment methods. Loud PubMed It is mainly autoantibodies that play a role and represent an important diagnostic marker. Unfortunately, there are hardly any prognostic biomarkers that go beyond clinical assessment.
In the long term, it is hoped that the new therapy will not only reduce symptoms, but also prevent relapses and restore quality of life for patients. According to the researchers, a one-time administration of the reprogrammed T cells could even cure the disease - a glimmer of hope that many affected people are waiting for.
As we can see, the project that began in the laboratory six years ago is now on its way to practical application. It remains exciting to see how this novel approach can not only treat NMDA receptor encephalitis, but perhaps also apply to other autoimmune encephalopathies. The team around Professor Harald Prüß is working hard on this promising treatment - a real sign of progress in neurology.
If you would like to find out more about the fascinating aspects of this research, you can find further information on the website Charité and from DZNE.